Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | — | -32.57M | -41.31M | -0.89 |
| 2023 FY | — | — | -23.41M | -27.03M | -0.56 |
| 2024 FY | — | — | -27.55M | -62.29M | -1.02 |
| 2025 FY | — | -105.00K | -42.97M | -15.28M | -0.19 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 68.24M | 12.13M | 13.16M | 2.60M | 56.12M |
| 2023 FY | 45.55M | 6.87M | 12.62M | 1.37M | 38.68M |
| 2024 FY | 68.91M | 36.34M | 8.74M | 1.12M | 32.57M |
| 2025 FY | 71.12M | 9.91M | 4.58M | 937.00K | 61.21M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -27.02M | -269.00K | -27.29M | — | -50.30M |
| 2023 FY | -23.94M | -34.00K | -23.97M | — | -539.00K |
| 2024 FY | -25.42M | — | -25.42M | — | -3.88M |
| 2025 FY | -32.80M | -174.00K | -32.97M | — | -4.16M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 39.57M | 29.01M | — | — | — |
| 2023 FY | 84.52M | 73.28M | — | — | — |
| 2024 FY | 326.27M | 318.65M | — | — | — |
| 2025 FY | 608.03M | 604.39M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | — | -10.26M | -8.00M | -0.10 |
| 2025 Q3 | — | — | -10.57M | -10.16M | -0.12 |
| 2025 Q4 | — | -26.00K | -12.22M | -12.32M | -0.18 |
| 2026 Q1 | — | -29.00K | -14.88M | -13.69M | -0.15 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 89.46M | 9.23M | 14.69M | 1.08M | 80.23M |
| 2025 Q3 | 80.47M | 8.71M | 2.87M | 1.01M | 71.77M |
| 2025 Q4 | 71.12M | 9.91M | 4.58M | 937.00K | 61.21M |
| 2026 Q1 | 253.20M | 12.52M | 40.10M | 834.00K | 240.68M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -5.78M | -113.00K | -5.89M | — | 9.69M |
| 2025 Q3 | -9.57M | — | -9.57M | — | -11.82M |
| 2025 Q4 | -9.19M | -25.00K | -9.22M | — | 1.71M |
| 2026 Q1 | -10.37M | -91.00K | -10.47M | — | 35.53M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 311.10M | 297.49M | — | — | — |
| 2025 Q3 | 610.50M | 608.65M | — | — | — |
| 2025 Q4 | 608.03M | 604.39M | — | — | — |
| 2026 Q1 | 1.32B | 1.28B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |